Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature
The development of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of patients with advanced stage cancers. However, immune-related adverse events are frequently observed. Cardiac toxicity from ICI therapy can range from asymptomatic troponin-I elevations to conduction abnormali...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2019-03-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/498985 |
| id |
doaj-050b36a63cac4605ad2f222a88150cca |
|---|---|
| record_format |
Article |
| spelling |
doaj-050b36a63cac4605ad2f222a88150cca2020-11-25T00:34:24ZengKarger PublishersCase Reports in Oncology1662-65752019-03-0112126027610.1159/000498985498985Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the LiteratureNikhil AgrawalArjun KhungerPankit VachhaniTeresa A. ColvinAlexander HattoumEdward SpangenthalAnne B. CurtisGrace K. DyMarc S. ErnstoffIgor PuzanovThe development of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of patients with advanced stage cancers. However, immune-related adverse events are frequently observed. Cardiac toxicity from ICI therapy can range from asymptomatic troponin-I elevations to conduction abnormalities of the heart and even fulminant myocarditis. Although rare, myocarditis is a potentially fatal adverse effect of ICI therapy. We present a series of five cases of ICI-related cardio-toxicity diagnosed and managed at Roswell Park Comprehensive Cancer Center along with a review of published case reports in the literature. Our series highlights the importance of high clinical suspicion, early diagnosis of myocarditis, and prompt initiation of immunosuppressive therapy.https://www.karger.com/Article/FullText/498985CardiotoxicityImmune checkpoint inhibitorsMyocarditisAutoimmuneCardio-oncology |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Nikhil Agrawal Arjun Khunger Pankit Vachhani Teresa A. Colvin Alexander Hattoum Edward Spangenthal Anne B. Curtis Grace K. Dy Marc S. Ernstoff Igor Puzanov |
| spellingShingle |
Nikhil Agrawal Arjun Khunger Pankit Vachhani Teresa A. Colvin Alexander Hattoum Edward Spangenthal Anne B. Curtis Grace K. Dy Marc S. Ernstoff Igor Puzanov Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature Case Reports in Oncology Cardiotoxicity Immune checkpoint inhibitors Myocarditis Autoimmune Cardio-oncology |
| author_facet |
Nikhil Agrawal Arjun Khunger Pankit Vachhani Teresa A. Colvin Alexander Hattoum Edward Spangenthal Anne B. Curtis Grace K. Dy Marc S. Ernstoff Igor Puzanov |
| author_sort |
Nikhil Agrawal |
| title |
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature |
| title_short |
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature |
| title_full |
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature |
| title_fullStr |
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature |
| title_full_unstemmed |
Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature |
| title_sort |
cardiac toxicity associated with immune checkpoint inhibitors: case series and review of the literature |
| publisher |
Karger Publishers |
| series |
Case Reports in Oncology |
| issn |
1662-6575 |
| publishDate |
2019-03-01 |
| description |
The development of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of patients with advanced stage cancers. However, immune-related adverse events are frequently observed. Cardiac toxicity from ICI therapy can range from asymptomatic troponin-I elevations to conduction abnormalities of the heart and even fulminant myocarditis. Although rare, myocarditis is a potentially fatal adverse effect of ICI therapy. We present a series of five cases of ICI-related cardio-toxicity diagnosed and managed at Roswell Park Comprehensive Cancer Center along with a review of published case reports in the literature. Our series highlights the importance of high clinical suspicion, early diagnosis of myocarditis, and prompt initiation of immunosuppressive therapy. |
| topic |
Cardiotoxicity Immune checkpoint inhibitors Myocarditis Autoimmune Cardio-oncology |
| url |
https://www.karger.com/Article/FullText/498985 |
| work_keys_str_mv |
AT nikhilagrawal cardiactoxicityassociatedwithimmunecheckpointinhibitorscaseseriesandreviewoftheliterature AT arjunkhunger cardiactoxicityassociatedwithimmunecheckpointinhibitorscaseseriesandreviewoftheliterature AT pankitvachhani cardiactoxicityassociatedwithimmunecheckpointinhibitorscaseseriesandreviewoftheliterature AT teresaacolvin cardiactoxicityassociatedwithimmunecheckpointinhibitorscaseseriesandreviewoftheliterature AT alexanderhattoum cardiactoxicityassociatedwithimmunecheckpointinhibitorscaseseriesandreviewoftheliterature AT edwardspangenthal cardiactoxicityassociatedwithimmunecheckpointinhibitorscaseseriesandreviewoftheliterature AT annebcurtis cardiactoxicityassociatedwithimmunecheckpointinhibitorscaseseriesandreviewoftheliterature AT gracekdy cardiactoxicityassociatedwithimmunecheckpointinhibitorscaseseriesandreviewoftheliterature AT marcsernstoff cardiactoxicityassociatedwithimmunecheckpointinhibitorscaseseriesandreviewoftheliterature AT igorpuzanov cardiactoxicityassociatedwithimmunecheckpointinhibitorscaseseriesandreviewoftheliterature |
| _version_ |
1725313556248788992 |